AI assistant
Sending…
Monopar Therapeutics — Director's Dealing 2023
Feb 4, 2023
32883_dirs_2023-02-03_785fc031-08a2-4fcb-9587-df1661e478f1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2023-02-01
Reporting Person: Tsuchimoto Kim R (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-01 | Stock Options | $3.16 | A | 102688 | Acquired | 2033-02-01 | Common Stock (102688) | Direct |
| 2023-02-01 | Restricted Stock Units | $0 | A | 78234 | Acquired | Common Stock (78234) | Direct |
Footnotes
F1: Options vest 6/48ths on June 30, 2023 and 1/48th per month thereafter.
F2: RSUs vest 6/48ths on June 30, 2023 and 3/48ths per quarter thereafter (September 30, 2023, December 31, 2023, March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024, March 31, 2025, June 30, 2025, September 30, 2025, December 31, 2025, March 31, 2026, June 30, 2026, September 30, 2026, December 31, 2026)